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ABSTRACT  24 
Vesicular stomatitis virus Indiana strain G protein (VSVind.G) is the most commonly 25 
used envelope glycoprotein to pseudotype lentiviral vectors (LV) for experimental 26 
and clinical applications.  Recently, G proteins derived from other vesiculoviruses 27 
(VesG), for example Cocal virus, have been proposed as alternative LV envelopes 28 
with possible advantages compared to VSVind.G.  Well-characterised antibodies that 29 
recognise VesG will be useful for vesiculovirus research, development of G protein-30 
containing advanced therapy medicinal products (ATMPs), and deployment of 31 
VSVind-based vaccine vectors.  Here we show that one commercially available 32 
monoclonal antibody, 8G5F11, binds to and neutralises G proteins from three strains 33 
of VSV as well as Cocal, and Maraba viruses, whereas the other commercially 34 
available monoclonal anti-VSVind.G antibody, IE9F9, binds to and neutralises only 35 
VSVind.G.  Using a combination of G protein chimeras and site-directed mutations, 36 
we mapped the binding epitopes of IE9F9 and 8G5F11 on VSVind.G. IE9F9 binds 37 
close to the receptor binding site and competes with soluble low-density lipoprotein 38 
receptor (LDLR) for binding to VSVind.G, explaining its mechanism of neutralisation. 39 
In contrast, 8G5F11 binds close to a region known to undergo conformational 40 
changes when the G protein moves to its post-fusion structure, and we propose that 41 
8G5F11 cross-neutralises VesGs by inhibiting this.  42 
IMPORTANCE 43 
VSVind.G is currently regarded as the gold-standard envelope to pseudotype 44 
lentiviral vectors.  However, recently other G proteins derived from vesiculoviruses 45 
have been proposed as alternative envelopes.  Here, we investigated two 46 
commercially available anti-VSVind.G monoclonal antibodies for their ability to cross-47 
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react with other vesiculovirus G proteins, and identified the epitopes they recognise, 48 
and explored their neutralisation activity.  We have identified 8G5F11, for the first 49 
time, as a cross-neutralising antibody against several vesiculovirus G proteins.  50 
Furthermore, we elucidated the two different neutralisation mechanisms employed 51 
by these two monoclonal antibodies.  Understanding how cross-neutralising 52 
antibodies interact with other G proteins may be of interest in the context of host-53 
pathogen interaction and co-evolution as well as providing the opportunity to modify 54 
the G proteins and improve G protein-containing medicinal products and vaccine 55 
vectors. 56 
INTRODUCTION 57 
The rhabdovirus, vesicular stomatitis virus Indiana stain (VSVind), has been used 58 
ubiquitously as a model system to study humoral and cellular immune responses in 59 
addition to being a promising virus for oncolytic virotherapy against cancer (1-3).  60 
Furthermore, its single envelope G protein (VSVind.G) is the most commonly used 61 
envelope to pseudotype lentiviral vectors and serves as the gold-standard in many 62 
experimental and clinical studies (4-6).  Both receptor recognition and membrane 63 
fusion of the wild-type virus, as well as the pseudotyped particles, are mediated by 64 
this single transmembrane viral glycoprotein that homotrimerises and protrudes from 65 
the viral surface (7-9).  Recently G proteins derived from other vesiculovirus 66 
subfamily members, namely, Cocal, Piry, and Chandipura viruses, have been 67 
proposed as alternative envelopes for lentiviral vector production due to some 68 
possible advantages over VSVind.G (10-12). 69 
Although some antigenic and biochemical characteristics of VSVind.G have been 70 
reported (1, 7, 13-20), there is still little known about the other vesiculovirus G 71 
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proteins (VesG) and there is a general lack of reagents commercially available to 72 
identify, detect, and characterise them.  In the past, monoclonal antibodies (mAbs) 73 
have been used to extensively study the antigenic determinants found on viral 74 
glycoproteins, e.g. hemagglutinin (HA) of influenza virus, the gp70 protein of murine 75 
leukaemia virus (MLV), and rabies virus G protein (21-25).  These previous studies, 76 
especially on the influenza virus strains and the rabies virus have led to invaluable 77 
findings on the structure and function of the glycoproteins allowing identification of 78 
epitopes essential in virus neutralisation (25-27).  In addition, mAbs have proven 79 
useful in viral pathogenesis studies as mutants selected by antibodies, in many 80 
cases demonstrated altered pathogenicity to their wild-type counterparts (28-30).  81 
Therefore, identification of antibodies that recognise VesG will not only be extremely 82 
valuable for vesiculovirus research but also aid in the development of G protein-83 
containing advanced therapy medicinal products (ATMP) and vaccine vectors. 84 
Here we show two anti-VSVind.G antibodies, 8G5F11 and a goat polyclonal 85 
antibody, VSV-Poly (31, 32), can cross-react with a variety of the VesG and cross-86 
neutralise VesG-LV.  We also demonstrate that the other commercially available 87 
extracellular monoclonal anti-VSVind.G antibody IE9F9 lacks this cross-reactivity.   88 
We further characterise the two mAbs, 8G5F11 and IE9F9, with regards to their 89 
relative affinities towards various VesG, binding epitopes, and cross-neutralisation 90 
strengths.   91 
RESULTS 92 
Investigation of antibody cross-reactivity with VesG 93 
To investigate antibody binding to different vesiculovirus envelope glycoproteins (G 94 
proteins), we prepared plasmid pMD2-based vectors expressing six different 95 
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vesiculovirus G proteins (VesG): VSVind.G, Cocal virus G (COCV.G), Vesicular 96 
stomatitis virus New Jersey strain G (VSVnj.G), Piry virus G (PIRYV.G), Vesicular 97 
stomatitis virus Alagoas strain G (VSVala.G), and Maraba virus G (MARAV.G) 98 
(Figure 1A).  HEK293T cells were transfected with these plasmid constructs, stained 99 
with the different antibodies, and analysed via flow cytometry.  While IE9F9 only 100 
bound to VSVind.G, anti-VSVind.G monoclonal antibody 8G5F11 and VSV-Poly both 101 
could recognise various VesG with varying binding strengths (Figure 1B).  PIRYV.G, 102 
the most distant vesiculovirus G investigated with approximately 40% identity to 103 
VSVind.G on amino acid level, could be recognised by VSV-Poly while 8G5F11 did 104 
not bind to it. 105 
Characterisation of IE9F9 binding, 8G5F11 cross-reactivity and its affinity 106 
towards other VesG 107 
To confirm that the difference of 8G5F11 binding to VesG was indicative of the mAb 108 
affinity towards VesG and not a difference in relative expression levels of the G 109 
proteins, we synthesised chimeric G proteins.  The endogenous transmembrane and 110 
C-terminal domains of VesG were switched with that of VSVind.G (Figure 2A).  111 
Following the expression of these chimeric G proteins in HEK293T cells, we 112 
investigated 8G5F11 and IE9F9 binding saturation using quantitative flow cytometry 113 
while the relative expression levels of the G proteins were monitored using an 114 
intracellular anti-VSVind.G mAb, P5D4 (Figure 2B).  8G5F11 showed a wide range 115 
of affinities towards VesG: while its affinity for MARAV.G was comparable to that of 116 
VSVind.G, its interactions with COCV.G and VSVnj.G were much weaker.   117 
To consolidate this finding, we further investigated these mAb-G protein interactions 118 
via surface plasmon resonance (SPR).  First, to quantify mAb binding to G protein 119 
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monomers under conformationally correct folding, we immobilised wild-type (wt) 120 
VSVind.G produced by thermolysin limited proteolysis of viral particles (Gth)  (7, 17) 121 
and tested the dose-dependent binding of the two mAbs (Figure 2C-D).  The 122 
measured Kd values for 8G5F11 and IE9F9 binding to VSVind.G were 2.76nM and 123 
14.7nM respectively.  To further analyse the VesG-8G5F11 interaction we 124 
immobilised the mAb and investigated VesG pseudotyped lentiviral vector (LV) 125 
binding.  Since pseudotyped LV particles contain many trimeric G protein spikes 126 
(33),  the analysis of the interaction between VesG binding to immobilised 8G5F11 127 
reflects avidity.  A specific, vector dose-dependent binding (i.e. increasing binding 128 
response with increasing titres) of  VSVind.G was detected which saturated faster 129 
than the mAb-Gth interaction. (Figure 2E).  When identical doses of VesG-LV at 130 
1x108 TU/ml were injected on immobilised 8G5F11, similar patterns of binding were 131 
observed to that of quantitative flow cytometry, in the order of strength of VSVind > 132 
MARAV > VSVala > Cocal > VSVnj (Figure 2F).  Unrelated RDpro envelope 133 
pseudotyped LVs were utilised as negative control to deduce unspecific interaction 134 
of enveloped particles with immobilised mAb.  PIRYV.G-LV demonstrated a similar 135 
response to that of RDpro-LV indicative of the lack of binding between the G protein 136 
and 8G5F11. 137 
Determining the cross-neutralisation abilities of anti-VSVind.G antibodies 138 
These three antibodies were evaluated for their ability to neutralise VSVind.G and 139 
VesG pseudotyped LVs (Figure 3).  8G5F11 demonstrated varying strengths of 140 
neutralisation against VesG pseudotyped LVs, IC50 values ranging from 11.5ng/ml 141 
to 86.9µg/ml (Figure 3A).  There was however limited correlation between G 142 
proteins’ binding strength and sensitivity of LV, e.g. VSVnj.G-LV was more sensitive 143 
than COCV.G-LV (Figure 3A) while COCV.G binding was stronger (Figure 1 and 2).  144 
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IE9F9 neutralised only VSVind.G-LV at 137ng/ml IC50, about 12-fold weaker than 145 
8G5F11 (Figure 3B).  In the case of VSV-Poly, we only observed cross neutralisation 146 
at high serum concentrations (Figure 3C).  Furthermore, although VSV-Poly bound 147 
to PIRYV.G, it did not neutralise PIRYV.G-LVs.  148 
Mapping the epitopes of anti-VSVind.G mAbs and identification of key amino 149 
acid residues that dictate antibody binding and neutralisation 150 
To map where the neutralising antibodies might bind to on the G protein surface a 151 
series of chimeric G proteins between VSVind.G and COCV.G were constructed.  152 
The initial binding and neutralisation studies performed with these chimeras enabled 153 
us to narrow down the epitopes of these mAbs to lie between amino acid (aa) 154 
residues 137-369 on VSVind.G (data not shown).  Furthermore, looking at previously 155 
published data on 8G5F11 and IE9F9’s epitopes obtained through mutant virus 156 
escape assays (1, 13-15) we concentrated on two distinct regions on VSVind.G and 157 
synthesised 22 different mutant G proteins to study the epitopes (Figure 4).  The 158 
mutants were cloned into the pMD2 backbone and their functionality were 159 
investigated via LV infection and antibody binding assays. All G proteins were 160 
confirmed to be functional and could successfully pseudotype LVs yielding 161 
comparable titres to their wild-type (wt) counterparts.  Furthermore, their relative 162 
expression levels were monitored by intracellular P5D4 which also recognises the 163 
intracellular domain of COCV.G.  Lastly, they could be detected by extracellular 164 
VSV-Poly implying there weren’t any substantial protein display issues (data not 165 
shown). 166 
We first investigated antibody binding to these G proteins via flow cytometry.  167 
Extracellular VSV-Poly and intracellular P5D4 stains determined relative expression 168 
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levels of the mutants.  For both sets the relative difference between expression 169 
levels of mutant and wt proteins was in most cases less than two-fold (Figure 5A-B).  170 
In the case of 8G5F11, binding to VSVind.G mutants was reduced by approximately 171 
100-fold while the changes on COCV.G enabled these mutants to bind to 8G5F11 at 172 
similar levels to that of wt VSVind.G (Figure 5C).  This change in binding could also 173 
be observed on a western blot:  while none of the VSVind.G mutants could be 174 
visualised, 8G5F11 could bind to COCV.G chimera C8.3 (data not shown).  It can be 175 
inferred from these results that aa 257-259 (DKD) are the key residues that dictate 176 
8G5F11 binding to G proteins. 177 
On the other hand, for IE9F9 no statistically significant changes in antibody binding 178 
were observed for VSVind.G mutants (data not shown) except for chimeras V1.2 and 179 
V1.4 (Figure 5D). However, there was a substantial gain of binding effect for 180 
COCV.G mutants.  While IE9F9 does not bind to wt COCV.G, mutations of amino 181 
acid residues LSR and AA (Figure 4) alone led to significant increase in the 182 
fluorescence signal, thus antibody binding, C1.4 with both LSR and AA had a 183 
comparable MFI level to that of wt VSVind.G.   184 
Neutralisation profile of both VSVind.G and COCV.G mutants was also examined 185 
(Figure 5E-H). While LVs pseudotyped with VSVind.G mutants G, A, and N were not 186 
neutralised by 8G5F11 (Figure 5E), varying degrees of sensitivity were observed for 187 
COCV.G mutants with the strongest binder being the most sensitive (Figure 5F).  On 188 
the other hand, this was not the case for IE9F9 mutants.  While dose-dependent 189 
neutralisation of V1.2-LV was observed, VSVind.G mutant V1.4-LV was resistant to 190 
IE9F9 neutralisation (Figure 5G).  Furthermore, no effect was observed on COCV.G 191 
mutant LV infection even though all bound to the mAb, some at similar levels to wt 192 
VSVind.G (Figure 5H).  The data shows that while 8G5F11 employs a neutralisation 193 
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mechanism that is effective amongst the tested VesG, IE9F9’s is VSVind.G specific 194 
and binding does not necessarily result in neutralisation. 195 
Investigation of neutralisation mechanisms utilised by the mAbs: binding 196 
competition with low-density lipoprotein receptor (LDLR) 197 
Antibodies neutralise viruses and viral vectors by several mechanisms.  Many 198 
neutralising antibodies (NAbs) prevent virions from interacting with cellular receptors 199 
(34).  VSVind.G’s major receptor has been identified as the low-density lipoprotein 200 
receptor (LDLR) (33, 35).  Therefore, we investigated the binding competition 201 
between 8G5F11 and IE9F9 with LDLR via SPR as a potential neutralisation 202 
mechanism for the mAbs (Figure 6).  Gth immobilised on the chip surface was 203 
saturated with repeated injections of 8G5F11 and IE9F9.  This was followed by an 204 
injection of recombinant soluble human LDLR (sLDLR) and its binding to Gth was 205 
examined.  While sLDLR was able to bind to Gth following 8G5F11 saturation as well 206 
as Gth without antibody exposure (buffer control), this interaction was almost 207 
completely abrogated by IE9F9.  These data suggest that IE9F9, but not 8G5F11, 208 
neutralises VSVind.G-LV by blocking the G protein-receptor interaction either 209 
through steric hindrance or direct competition. 210 
8G5F11 blocks infection after endocytosis and before genome reverse 211 
transcription 212 
As demonstrated by the SPR data, 8G5F11 did not block receptor binding of the G 213 
protein implying that it may be acting on LV infection steps following receptor 214 
binding.  Therefore, we investigated the internalisation of 8G5F11 bound LV particles 215 
(Figure 7A).  For this VSVind.G- and RDpro-LV, as well as unenveloped (env -ve) 216 
LVs, were incubated with mAbs or plain OptiMEM and plated on HEK293T cells.  217 
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The level of LV which was internalised and therefore resistant to cell-trypsinisation 218 
was measured through reverse transcriptase (RT) activity 30min post-infection.  RT 219 
activity measured in env -ve samples were regarded as unspecific uptake and 220 
regarded as background.  RDpro-LVs, regardless of incubation with anti-VSVind.G 221 
mAbs, were internalised and so were VSVind.G-LVs in OptiMEM.  While VSVind.G-222 
LV incubated with IE9F9 demonstrated RT activity levels comparable to that of 223 
unenveloped LVs, 8G5F11 bound LV particles were endocytosed displaying RT 224 
activity similar to that of OptiMEM mixed VSVind.G-LV.  In parallel infections total 225 
DNA was harvested 5h post-infection from VSVind.G-LV infected samples to 226 
determine reverse-transcribed provirus and transgene (GFP) copies via quantitative 227 
PCR and GFP expression was determined 48 post-infection via flow cytometry 228 
(Figure 7B).  Reverse-transcribed LV copies and GFP expression were only detected 229 
in no mAb infections.  Taken together, the data suggest that 8G5F11 blocks 230 
VSVind.G-LV infection following receptor binding and endocytosis of the vectors and 231 
before genome reverse transcription. 232 
DISCUSSION 233 
VSVind.G is the most commonly used envelope glycoprotein to pseudotype LVs for 234 
experimental and clinical applications.  VSVind.G pseudotyped LVs can be produced 235 
in high titres and can infect a range of target cells.  However, VSVind.G is cytotoxic 236 
to cells; thus, it is difficult to express it constitutively (36, 37).  Moreover, VSVind.G 237 
pseudotyped LVs can be inactivated by human serum complement which limits their 238 
potential in vivo use (38-42).  Therefore, there is a clear need for alternative 239 
envelopes to pseudotype LVs.  Some of the most recent alternative envelopes that 240 
have been utilised are the G proteins of the other vesiculovirus family members (10-241 
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12).  However, one drawback of using these new G proteins is that there are no 242 
reagents commercially available to identify or characterise them. 243 
In this study, we report that a commercially available anti-VSVind.G monoclonal 244 
antibody 8G5F11 can, unlike VSVind.G specific IE9F9, cross-react with a variety of 245 
the VesG and cross-neutralise VesG-LV.  Furthermore, we explored the functional 246 
epitopes for both mAbs, identifying new amino acid substitutions in addition to 247 
previously reported ones (15), and elucidated their mechanism of neutralisation.  G 248 
proteins of vesiculoviruses other than VSVind are being utilised for LV pseudotyping 249 
with the construction COCV.G-LV producer clones for gfp and T cell receptor-250 
encoding LVs and the use of PIRYV.G and CHAV.G in transient LV production have 251 
been reported  (10, 12, 43).  We believe that the work presented will lay the 252 
groundwork for adaptation of VesG into new G-protein based advanced therapy 253 
medicinal products and allow for the utilisation of these commercially available 254 
antibodies in vesiculovirus and VesG-based gene therapy research. 255 
The cross-reactive monoclonal 8G5F11 demonstrated interesting characteristics.  Its 256 
high cross-reactivity even towards more distant relatives of VSVind.G such as 257 
VSVnj.G suggested that it might be recognising a well-conserved epitope.  However, 258 
the results of the binding saturation assay didn’t correlate with phylogenetic relativity.  259 
It revealed that its affinity towards COCV.G, one of the closest relatives of VSVind.G, 260 
was one of the weakest amongst the VesG investigated with almost a 250-fold 261 
difference compared to VSVind.G (Figure 2B).   262 
This discrepancy can be explained through fine mapping of the 8G5F11 epitope.  We 263 
identified the amino acids 257-259, DKD, as the key residues on VSVind.G for 264 
8G5F11 binding.  On VSVind.G the two negatively charged aspartic acid residues 265 
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flank the positively charged lysine possibly contributing towards the structure of the 266 
α-helix form through salt-bridges (7, 16, 17).  When either of the aspartic acid 267 
residues is mutated to a neutral residue a significant reduction in binding is 268 
observed.  When this is compared to the corresponding three residues on other 269 
VesG, the antibody binding is dependent on the overall charge of these three 270 
residues rather than the ones surrounding them.  In MARAV.G, these residues are 271 
identical to VSVind.G, explaining why the antibody has similar strength of binding to 272 
these two G proteins (Figure 8).  On the other hand, VSVala.G binds 8G5F11 with 273 
high affinity although these residues are not fully conserved, as in VSVala.G the 274 
second aspartic acid residue is replaced with a glutamic acid.  But it is possible that 275 
the conservation of the second negative charge and the structural similarities 276 
between these two residues enable a robust G protein-antibody interaction.  Lastly, 277 
the corresponding aa residues in PIRYV.G, VEQ, have electrostatically and 278 
structurally different characteristics to that of lysine and aspartic acid leading to the 279 
lack of interaction between the mAb and G protein. 280 
We showed that IE9F9 recognises a β-sheet rich domain of the G protein (7, 17).  A 281 
complete abrogation of binding wasn’t observed with the VSVind.G mutants 282 
produced.  This implies that the antibody either relies on other structural cues and 283 
environmental charges around for binding or can utilise a secondary epitope.  284 
However, through the gain of binding effect observed in COCV.G mutants, we were 285 
able to identify two regions; AA and LSR, aa residues 352-353 and 356-358 286 
respectively on VSVind.G, that are the key to this antibody’s interaction.   287 
All three reagents investigated demonstrated neutralising activities.  8G5F11 had the 288 
greatest ability to cross-neutralise a wide array of vesiculovirus family members.  289 
The strength of neutralisation for this mAb, however, didn’t correlate with its affinity 290 
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towards other VesG (Figure 2 and 3).  This suggests that innate differences, such as 291 
protein structure, between the VesG might be playing a role in LV neutralisation.  292 
Since the structures of the VesG other than VSVind.G and CHAV.G are not yet 293 
delineated, it is hard to point out the key factors and mechanism involved accurately.  294 
However, we have identified 8G5F11’s epitope to lie close to the cross-over point 295 
between pleckstrin homology and trimerisation domain of VSVind.G (7, 17, 19, 20, 296 
35).  Several hinge segments have been identified in the proximity of the epitope 297 
which undergo large rearrangements in its relative orientation while the G protein 298 
refolds from pre to post-fusion conformation in the low-pH conditions of the 299 
endosomes following endocytosis (16, 19, 35).  It can be hypothesised that 8G5F11 300 
might be hindering this process ultimately preventing viral fusion and infection.  As 301 
pH-induced conformational changes during viral fusion is a shared characteristic 302 
amongst VesG (44), this might be the underlying reason behind 8G5F11’s ability to 303 
cross-neutralise VesG-LV. 304 
We have shown that IE9F9 blocks VSVind.G binding to its major receptor LDLR 305 
(Figure 6).  The crystal structures of VSVind.G in complex with LDLR domains have 306 
been recently identified and have shown that VSVind.G can interact with two distinct 307 
cysteine-rich domains (CR2 and CR3) of LDLR (35).    One of the regions on 308 
VSVind.G that is crucial for LDLR CR domain binding lies between amino acids 366-309 
370, only seven amino acids away from the key residues in IE9F9’s epitope.  The 310 
key residues in this region of VSVind.G are not conserved amongst vesiculoviruses 311 
therefore, neither the use of this epitope nor LDLR can be generalised to the other 312 
members of the genus, making IE9F9’s epitope and neutralisation mechanism 313 
specific to VSVind.G.  The lack of cross-reactivity and cross-neutralisation (Figure 1 314 
and 3) displayed by the mAb towards VesG as well as its failure to neutralise 315 
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COCV.G mutants when its epitope is inserted into the G protein (Figure 5) suggest 316 
specific requirement for binding mode between IE9G9 and G proteins to result in 317 
neutralisation.  Nikolic and colleagues have demonstrated that VSVind.G has 318 
specifically evolved to interact with the CR domains of other LDLR family members 319 
(35).    The other members of the receptor family have already been identified as 320 
secondary ports of entry for the virus (33).  Complete neutralisation achieved with 321 
IE9F9 indicates that the other LDLR family members might be interacting with the 322 
same epitope on VSVind.G as well. 323 
On the other hand, 8G5F11 does not interfere with receptor recognition (Figure 6) 324 
and allows internalisation of the LV particles by the target cells (Figure 7A).  325 
However, the vector genome does not get reverse transcribed and infection does not 326 
occur implying 8G5F11 interferes with infection mechanisms after receptor binding 327 
and internalisation of the particles.  As discussed above 8G5F11’s epitope is located 328 
at the PH domain of the G protein in an α-helix around hinge regions that undergo 329 
structural rearrangement.  Our results, therefore, suggest that 8G5F11 may 330 
neutralise VesG by interfering such conformational changes and membrane fusion. 331 
Further work on these two identified epitopes regarding their immunodominance in 332 
an in vivo setting and their detailed characterisation on other VesG from the 333 
structure-function point of view may be of interest in the context of host-pathogen 334 
interaction and co-evolution.   This may also provide the opportunity for modifying 335 
VSVind.G to improve G protein-containing advanced therapy medicinal products and 336 
VSVind-based vaccine vectors. 337 
MATERIALS AND METHODS 338 
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Cell culture. In all experiments, HEK293T cells were used.  The cell line was 339 
maintained in Dulbecco's Modified Eagle Medium (DMEM) (Sigma-Aldrich, St Louis, 340 
MO) supplemented with 10% heat-inactivated foetal calf serum (Gibco, Carlsbad, 341 
CA), 2mM L-Glutamine (Gibco), 50 units/ml Penicillin (Gibco), 50µg/ml Streptomycin 342 
(Gibco).  All cells were kept in cell culture incubators at 37ºC and 5% CO2. 343 
Phylogenetic analysis of vesiculovirus and rabies virus G proteins based on 344 
amino acid sequences. G proteins of the major vesiculoviruses (VSVind, UniProt 345 
Accession Number: P03522, Cocal virus, O56677, VSVnj, P04882, Piry virus, 346 
Q85213, Maraba virus, F8SPF4, VSVala, B3FRL4, Chandipura virus, P13180, 347 
Carajas virus, A0A0D3R1Y6, Isfahan virus, Q5K2K4) as well as the G protein of the 348 
Rabies virus (Q8JXF6), were included in the analysis. The amino acid sequences 349 
were aligned using ClustalOmega online multiple sequence alignment tool (EMBL-350 
EPI). The evolutionary analyses were conducted in MEGA7 (45).  The evolutionary 351 
history was inferred by using the maximum likelihood method based on the Jones-352 
Taylor-Thornton matrix-based model (46).  The tree with the highest likelihood is 353 
shown with the bootstrap confidence values (out of 100) indicated at the nodes. The 354 
tree is drawn to scale, with branch lengths measured in the number of substitutions 355 
per site, depicted in the linear scale.  It should be noted that the amino acid 356 
sequence of the full-length G proteins (including the signal peptide) were referred to 357 
in this manuscript. Accordingly, reference to specific residue numbers is made in the 358 
context of these full-length sequences. 359 
Plasmids used in experiments. VSVind.G expression plasmids, pMD2.G, and gag-360 
pol expression plasmid p8.91 (47) were purchased from Plasmid Factory (Germany).  361 
GFP expressing self-inactivating vector plasmid used in the production of lentiviral 362 
vectors was produced in our lab previously (48, 49).  pMD2.Cocal.G, COCV.G, 363 
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expression plasmid was a kindly provided by Hans-Peter Kiem (Fred Hutchinson 364 
Cancer Research Center, Seattle, WA) .  All other VesG envelopes were cloned into 365 
this backbone using the restriction enzymes PmlI and EcoRI.  Amino acid sequences 366 
for VSVnj.G, PIRYV.G, MARAV.G, VSVala.G were retrieved from UniProt.  Codon-367 
optimised genes were ordered from Genewiz (South Plainfield, NJ).  Unrelated feline 368 
endogenous virus RD114 derived RDpro envelope (49) was used as a negative 369 
control. 370 
Gene transfer to mammalian cells. Single plasmid transfection was used to 371 
express VesG on HEK293T cell surface. HEK293T cells were seeded on the day 372 
prior to transfection at 4x106 cell per 10cm plate.  These cells were transfected by 373 
lipofection using FuGENE6 (Promega, Madison, WI) according to the manufacturer’s 374 
instructions.  The cells were harvested 48h later to be used in various flow cytometry 375 
assays. 376 
Overlapping extension PCR to synthesise VesG chimeras.  Phusion High-377 
Fidelity PCR Kit (NEB, Ipswich, MA) was used to perform the PCR reactions.  All 378 
primers used were obtained from Sigma-Aldrich.  To splice two DNA molecules, 379 
special primers were at the joining ends. For each molecule, the first of two PCRs 380 
created a linear insert with a 5' overhang complementary to the 3’ end of the 381 
sequence from the other gene. Following annealing, these extensions allowed the 382 
strands of the PCR product to act as a pair of oversized primers and the two 383 
sequences were fused. Once both DNA molecules were extended, a second PCR 384 
was carried out with only the flanking primers to amplify the newly created double-385 
stranded DNA of the chimeric gene.  386 
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Surface plasmon resonance. Analyses were performed using a BIAcore T100 387 
instrument (GE Healthcare).  Gth (0.04 mg/mL) and 8G5F11 (0.03 mg/mL) in sodium 388 
acetate buffers (10mM, pH 4.5 and 4.0 respectively) were immobilised on a CM5 389 
sensor chip using the amine coupling system according to the manufacturer’s 390 
instructions.  To measure mAb affinity to VSVind.G, 8G5F11 (MW 155kDa) and 391 
IE9F9 (MW 155kDa) were suspended in HBS-EP (0.01M HEPES pH7.4, 0.15M 392 
NaCl, 3mM EDTA, 0.005v/v P20) and passed over the immobilised Gth at the 393 
indicated concentrations.  To measure VesG-LV avidity against 8G5F11, LV 394 
preparations were suspended in HBS-EP buffer and passed over the immobilised 395 
mAb at indicated titers.  The dissociation constants were calculated using 396 
BIAevaluation software according to the manufacturer’s instructions.  For the 397 
competitive binding assay, multiple injections of mAbs at 10µg/mL concentration was 398 
performed followed by injection of soluble recombinant LDLR (R&D Systems, 399 
Minneapolis, MN) at an identical concentration. 400 
Use of molecules of equivalent soluble fluorochrome (MESF) system for 401 
quantitative flow-cytometry analysis. Quantum Alexa Fluor 647 MESF kit (Bangs 402 
Laboratories, Fishers, IN) was utilised for all quantitative fluorescence flow cytometry 403 
experiments.  This is a microsphere kit that enables the standardisation of 404 
fluorescence intensity units.  Beads with a pre-determined number of fluorophores 405 
are run on the same day and at the same fluorescence settings as stained cell 406 
samples to establish a calibration curve that relates the instrument channel values 407 
(i.e. median fluorescence intensity (MFI)) to standardised fluorescence intensity 408 
(MESF) units.  409 
Extracellular and intracellular antibody binding assay.  HEK293T cells were 410 
transfected to express the G proteins. 48 hours later cells were harvested, washed 411 
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twice with PBS and plated in U-bottom 96-well plates at identical densities.  For 412 
intracellular antibody binding assays cells were fixed with 1% formaldehyde (Sigma-413 
Aldrich, St Louis, MO) in PBS, permeabilised using 0.05% saponin (Sigma-Aldrich, 414 
St Louis MO) in PBS and blocked with 1% bovine serum albumin (BSA, Sigma-415 
Aldrich, St Louis MO) in PBS.  Cells were then incubated with serial dilutions of 416 
extracellular and intracellular antibodies ranging from 0.1mg/ml to 2x10-7 mg/ml in 417 
1% BSA (Sigma) in PBS in a total reaction volume of 200µl.  After washing twice, 418 
each sample was incubated with its respective fluorophore-conjugated secondary 419 
antibody.  Cells were then washed twice and resuspended in PBS.  Stained cell 420 
samples were analysed via flow cytometry using a FACSCanto II (BD Biosciences, 421 
San Jose, CA) and Flowjo software.  Primary antibodies used are as follows: 422 
8G5F11 (I1 in (14)) and IE9F9 (I14 in (14)) (Kerafast, Boston, MA), VSV-Poly, a kind 423 
gift from Prof Hiroo Hoshino and Dr Atsushi Oue (31, 32), P5D4 (Sigma-Aldrich).  424 
Secondary antibodies used are as follows: Alexa Fluor® 647 conjugated anti-mouse 425 
and anti-goat IgG (cat # 115-605-164 and 305-605-046 respectively, Jackson 426 
Immunoresearch, UK). 427 
Transient LV production and concentration. Three-plasmid co-transfection into 428 
HEK293T cells was used to make pseudotyped LV as described previously (47). 429 
Briefly, 4x106 293T cells were seeded in 10cm plates. 24 hours later, they were 430 
transfected using FuGene6 (Promega, Madison, WI) with following plasmids: SIN 431 
pHV (GFP expressing vector plasmid (48, 49)), p8.91 (Gag-Pol expression plasmid 432 
(47)), and envelope expression plasmids. The medium was changed after 24 hours 433 
and then vector containing media (VCM) was collected over 24-hour periods for 2 434 
days. Following collection, VCM was passed through Whatman Puradisc 0.45µm 435 
filters (SLS) and concentrated ~100-fold by ultra-centrifugation at 22,000 rpm 436 
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(87,119xg) for 2 hours at 4ºC in Beckmann Optima LK-90 ultracentrifuge using the 437 
SW-28 swinging bucket rotor (radius 16.1cm).  The virus was resuspended in cold 438 
plain Opti-MEM on ice, aliquoted and stored at -80ºC.  439 
LV titration. The functional titre of each vector preparation was determined by flow 440 
cytometric analysis for GFP expression following transduction of HEK293T cells. 441 
Briefly, 2x105/well 293T cells were infected with LV plus 8 µg/ml polybrene (Merck-442 
Millipore, Billerica, MA) for 24 hours. Infected cells were detected by GFP expression 443 
at 48 hours following the start of transduction. Titres were calculated from virus 444 
dilutions where 1–20% of the cell population was GFP-positive using the following 445 
formula: 446 
Titre (
transduction units (TU)
ml
)
=  
(no.  of cells at transduction) ×  (% of GFP positive cells ÷ 100) × (dilution factor)
(the volume of virus preparation added (ml))
 
Antibody neutralisation assay. To determine the neutralisation activity of anti-447 
VSVind.G monoclonal and polyclonal antibodies an infection assay in the presence 448 
of antibodies was performed. Briefly, HEK293T cells were seeded in a 96-well plate 449 
at a density of 2x104 cells/well with 200µl of medium containing 8µg/ml polybrene.  450 
Approximately 3 hours later, antibodies were serially diluted in plain Opti-MEM to 12 451 
different concentrations/dilutions ranging from 0.5mg/ml (1:2 dilution) to 1.6x10-7 452 
mg/ml (1:6,250,000 dilution).  Each antibody dilution was mixed 1:1 with VesG-LV or 453 
mutant G-LV at 4.0x105TU/ml titre to a final volume of 20µl, incubated at 37ºC for 1h 454 
and plated on the cells.  48 hours after cells were harvested and analysed for GFP 455 
expression by flow cytometry.   456 
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Site-directed mutagenesis PCR for production of mutant G proteins for epitope 457 
mapping. Site-directed mutagenesis (SMD) method was utilized to produce G 458 
protein mutants that were used in epitope mapping experiments.  For this, 459 
QuikChange II XL Site-Directed Mutagenesis Kit (Agilent, Santa Clara, CA) was 460 
used. Initially, primers that would have the desired nucleotide changes were 461 
designed using the QuikChange Primer Design Tool 462 
(http://www.genomics.agilent.com/primerDesignProgram.jsp ).   All primers used 463 
were obtained from Sigma-Aldrich (St Louis, MO).   The reaction was carried out 464 
according to manufacturer’s instructions. 465 
SYBR Green product-enhanced reverse transcriptase (SG-PERT)-based LV 466 
internalisation assay and quantitative PCR Assay.    2x104 HEK293T cells/well 467 
were seeded in 24-well plates. 4.0x105TU/ml titre of VSVind.G- and RDpro-LV as 468 
well as unenveloped LV (at a similar dilution) were mixed 1:1 v/v with plain OptiMEM 469 
or 0.1mg/ml of 8G5F11 or IE9F9 to a total volume of 20µl, incubated 1h at 37°C, and 470 
plated on cells.  Following 30min incubation at 37°C samples for SG-PERT analysis 471 
(3 wells/condition) were harvested, washed and treated with trypsin-EDTA (0.25%) 472 
(Gibco) for 30min at 37°C.  After, cells were lysed, and the SG-PERT was carried out 473 
as previously described (50, 51).  In parallel, 5h post-incubation cells challenged with 474 
VSVind.G-LV were harvested (3 wells/condition) and total DNA was purified using 475 
the DNeasy Blood and Tissue Kit (Qiagen, Germany).  50ng of DNA was subjected 476 
to SYBR Green quantitative PCR using late RT (5’- CCCAACGAAGACAAGATCTGC-3’ 477 
and 5’- TCCCATCGCGATCTAATTCTCC-3’) and GFP (5’- 478 
CAACAGCCACAACGTCTATATCAT-3’ and 5’- ATGTTGTGGCGGATCTTGAAG-3’) 479 
primers to detect provirus as described previously (43).  β-actin (5’-480 
TGGACTTCGAGCAAGAGATG-3’ and 5’-TTAAGTAGGCCGTCTTGCCT-3’) was 481 
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used as the endogenous control.  Infectivity was measured in parallel samples by 482 
flow cytometry 48h post infection.  483 
Statistical Analyses.  All statistical analyses were performed using GraphPad Prism 484 
5 software (GraphPad, La Jolla, CA).  Details of all tests, including the calculated p-485 
values, are indicated in respective figure legends. 486 
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FIGURE LEGENDS 644 
Figure 1:  8G5F11 and VSV-Poly cross-react with a variety of VesG while IE9F9 645 
only binds to VSVind.G. (A) G proteins of the major vesiculoviruses, as well as the 646 
G protein of the rabies virus (RABV), were analysed with regards to their 647 
phylogenetic relationship. The tree amongst VesG is drawn to scale, with branch 648 
lengths measured in the number of substitutions per site, depicted in the linear scale. 649 
VSVind: Vesicular stomatitis virus Indiana strain, COCV: Cocal virus, VSVnj: 650 
Vesicular stomatitis virus New Jersey strain, PIRYV: Piry virus, CJSV: Carajas virus, 651 
CHAV: Chandipura virus, ISFV: Isfahan virus, MARAV: Maraba virus, VSVala: 652 
Vesicular stomatitis virus Alagoas strain. Vesiculoviruses that we investigated are 653 
highlighted in boxes and percentage amino acid identities to VSVind.G are 654 
summarised in the table on the right-hand side. (B)  Histograms represent the 655 
binding of the antibodies to the VesG expressed on the surface of transfected 656 
HEK293T cells.  The strength of cross-reaction is depicted via the different MFIs of 657 
the histograms. Data shown is one of the three repeats performed. 658 
Figure 2:  Investigation of 8G5F11 and IE9F9 affinities towards VSVind.G and 659 
characterisation of 8G5F11 cross-reactivity. (A) Schematic representation of the 660 
chimeric vesiculovirus G proteins with VSVind.G transmembrane and C-terminal 661 
domains. (B) HEK293T cells expressing chimeric VesG were incubated with serial 662 
dilutions of 8G5F11 and analysed via flow cytometry.  MFIs of the fluorescent signals 663 
were converted into the number of fluorophores using the MESF standard curve 664 
according to manufacturer’s instructions, the background signal from mock-665 
transfected HEK293Ts was subtracted and binding saturation curves were plotted.  666 
The varying affinity of the mAb towards different VesG is demonstrated by the shift in 667 
the slope of the binding curves. The curves were fitted, and dissociation constants 668 
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(Kd) calculated using the software GraphPad Prism 5 modelling the interaction as 669 
1:1 specific binding: VSVind.G: 2.64x10-9M, COCV.G: 5.88x10-7M, VSVnj.G: 670 
1.57x10-7M, MARAV.G: 4.13x10-9M, VSVala.G: 3.09x10-9M.  Data shown represent 671 
the mean of three repeats performed in duplicates. (inset) The expression levels of 672 
the chimeric G proteins were determined via intracellular P5D4 staining.  Data shown 673 
represent the mean +/- SD of three repeats performed in duplicates.  Surface 674 
plasmon resonance (SPR) analysis of (C) 8G5F11 and (D) IE9F9 binding to 675 
immobilized Gth in HBS-EP buffer.  (E)  Surface plasmon resonance analysis of 676 
VSVind.G-LV binding to immobilised 8G5F11 in HBS-EP buffer.  (F) Surface 677 
plasmon resonance analysis of Ves.G-LV (1x108 TU/ml) binding to immobilized 678 
8G5F11 in HBS-EP buffer.  The binding curves are normalised with regards to the 679 
relative response of unenveloped LV particles (Env -ve) which is regarded as the 680 
background.   SPR data shown is one of the three repeats performed. 681 
Figure 3:  Neutralisation activity of mAbs and VSV-Poly.  Neutralisation of VesG-682 
LV by (A) 8G5F11, (B) IE9F9, and (C) VSV-Poly.  Solid lines signify the 683 
neutralisation effect observed while the dotted lines indicate the lack of 684 
neutralisation.  (D) Calculated IC50 values for 8G5F11 and IE9F9, depicting the 685 
potency of neutralisation.  The curves were fitted using the software GraphPad Prism 686 
5 modelled as an [inhibitor] vs. response curve with variable Hill Slopes and IC50 687 
values calculated.  Data shown represent the mean +/- SD of three repeats. 688 
Figure 4:  Mutants and chimeric G proteins produced for epitope mapping. 689 
Mutants and chimeras produced for epitope mapping of monoclonal antibodies (A) 690 
8G5F11 and (B) IE9F9.  Names and linear representations of the mutants and 691 
chimeras are listed on either side of the amino acid alignments of the regions where 692 
mutations were made.  The boundaries are labelled with respective amino acid 693 
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numbers.  Amino acid alignment legend: Black, residues from wt VSVind.G; white 694 
with black background, residues from wt COCV.G; grey, shared residues; blue, 695 
previously identified mutants (15); red, VSVind.G residues switched into COCV.G; 696 
green, COCV.G residues switched into VSVind.G.  Linear G protein representations: 697 
the regions that the mutations were carried out at are represented by dotted lines. 698 
Black bars represent wt VSVind.G sequences while grey-bordered bars are for wt 699 
COCV.G residues.  Point mutations are denoted by a bar and a circle. 700 
Figure 5:  Investigation of antibody binding to mutant G proteins and 701 
neutralisation of mutant-LVs. HEK293T cells were transfected to express the 702 
mutant G proteins on their surface.  (A-B) The cells expressing chimeric mutants 703 
were stained with extracellular VSV-Poly (white bars) and intracellular P5D4 (grey 704 
bars) as expression control for the G proteins.  The measured MFI values were 705 
normalised to the wt VesG signals for each set of mutants.  The same population of 706 
cells were also incubated with (C) 8G5F11 and (D) IE9F9 at saturating 707 
concentrations. One-way ANOVA analysis with Dunnett’s post-test was performed to 708 
compare the MFI values of mutant G proteins to that of their wild-type counterpart.  709 
Legged lines denote the significance of a single comparison, while straight lines 710 
signify all the individual comparisons within the group share the denoted significance 711 
unless otherwise stated (*, p<0.05; **, p<0.01; ***, p<0.001).  This assay was 712 
performed three times in duplicates; mean +/- SD is plotted above.  The 713 
neutralisation curves for select mutant and chimeric G pseudotyped LVs are plotted 714 
for (E-F) 8G5F11 and (G-H) IE9F9.  Solid lines signify the neutralisation effect 715 
observed.  (E and G) Previously reported reductions in binding for VSVind.G 716 
mutants translated into either complete or partial resistance to neutralisation by both 717 
antibodies.  For COCV.G mutants (F and H), the mutations conferred the G proteins 718 
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sensitivity to neutralisation by 8G5F11 but not by IE9F9.  The curves were fitted 719 
using the software GraphPad Prism 5 modelled as an [inhibitor] vs. response curve 720 
with variable Hill Slopes.  Data shown represent the mean from three experiments 721 
performed in independent triplicates. 722 
Figure 6: IE9F9 hinders sLDLR binding to Gth.  8G5F11 and IE9F9 were injected 723 
over immobilised Gth at 10µg/ml concentration three times to achieve binding 724 
saturation.  Following this, sLDLR was injected over the chip at a concentration of 725 
10µg/ml and its binding to Gth was measured.  As buffer control an identical sLDLR 726 
injection was performed following multiple injections of HBS-EP running buffer.  727 
Measured sLDLR binding levels are indicated above the binding response curves 728 
and times of injections are marked with arrows.  The data presented represent one 729 
of the three repeats performed. 730 
Figure 7: Internalisation but not reverse transcription of 8G5F11 bound LVs.  731 
(A) VSVind.G- and RDpro-LVs as well as env -ve LVs were incubated with plain 732 
OptiMEM or 8G5F11 or IE9F9 and plated on HEK293T cells.  After allowing 733 
internalisation of the particles cells were lysed and RT activity measured via SG-734 
PERT.  The black bars represent the initial viral inputs plated on cells.  The data 735 
shown represent mean +/- SEM of two repeats performed in triplicates.  (B)  In 736 
parallel infections total DNA was extracted 5h post-infection and reverse-transcribed 737 
provirus and transgene copies were quantified via qPCR and normalised to β-actin 738 
copies.  The data shown represent mean +/- SEM of an experiment performed in 739 
independent triplicates. GFP expression was determined 48h post-infection via flow 740 
cytometry.  Each point represents an independent triplicate and the line stands for 741 
the median. 742 
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Figure 8: Comparison of 8G5F11’s epitope in other VesG through amino acid 743 
alignment.  Amino acid residues for the vesiculovirus G proteins were retrieved from 744 
UniProt. The sequences were aligned using ClustalOmega online multiple sequence 745 
alignment tool (EMBL-EPI), and the alignments were visualised using JalView 746 
software (52).  The boundaries are labelled with respective amino acid numbers.  747 
Dashed lines represent gaps introduced to maximise matching of amino acid 748 
residues. Blue shading indicates percent identity; dark blue: 80-100%, medium blue: 749 
60-80% light blue: 40-60%, and no colour indicating <40% identity.  Amino acid 750 
residues that dictate 8G5F11 binding are highlighted in a red box. 751 
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